| First Author | Campbell KJ | Year | 2018 |
| Journal | Cell Death Dis | Volume | 9 |
| Issue | 2 | Pages | 19 |
| PubMed ID | 29339815 | Mgi Jnum | J:339466 |
| Mgi Id | MGI:7522592 | Doi | 10.1038/s41419-017-0035-2 |
| Citation | Campbell KJ, et al. (2018) MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis 9(2):19 |
| abstractText | Analysis of publicly available genomic and gene expression data demonstrates that MCL1 expression is frequently elevated in breast cancer. Distinct from other pro-survival Bcl-2 family members, the short half-life of MCL-1 protein led us to investigate MCL-1 protein expression in a breast cancer tissue microarray and correlate this with clinical data. Here, we report associations between high MCL-1 and poor prognosis in specific subtypes of breast cancer including triple-negative breast cancer, an aggressive form that lacks targeted treatment options. Deletion of MCL-1 in the mammary epithelium of genetically engineered mice revealed an absolute requirement for MCL-1 in breast tumorigenesis. The clinical applicability of these findings was tested through a combination of approaches including knock-down or inhibition of MCL-1 to show triple-negative breast cancer cell line dependence on MCL-1 in vitro and in vivo. Our data demonstrate that high MCL-1 protein expression is associated with poor outcome in breast cancer and support the therapeutic targeting of MCL-1 in this disease. |
